(Page 4 of 5)
commercialize Lovidia by early 2014.
—In a separate announcement, Elcelyx said its long-acting formulation of the generic diabetes drug metformin is meeting its main goal of significantly reducing fasting blood plasma glucose among patients during the first four weeks of treatment of a mid-stage trial. Final results are expected in late October. Elcelyx said its delayed-release formulation drug candidate, dubbed NewMet, reduces nausea and vomiting that some Type 2 diabetic patients experience while on metformin.
—San Diego’s Allylix, an industrial biotechnology company, said it was named one of 15 companies to win a Defense Energy Technology Challenge by developing a renewable, high-quality, and cost-effective high density fuel comparable to JP-10, the Pentagon’s existing petroleum-based fuel standard. Allylix has developed technology to genetically engineer yeast to produce a wide range of terpene-based products. A spokeswoman for Allylix said its sustainably produced terpenes can be used directly as high density fuels or as additives to other hydrocarbons to improve the performance characteristics of a given fuel. The third annual Defense Energy Technology Challenge was managed by the Clean Technology and Sustainable Industries Organization in partnership with the U.S. Army, Navy and Air Force.